Infectious Diseases (Mass Gathering Testing for Coronavirus Disease 2019) (Amendment No. 10) Regulations 2021

Status:

Published in Subsidiary Legislation Supplement
on 09 Oct 2021

No. S 768

Infectious Diseases Act

(CHAPTER 137)

Infectious Diseases
(Mass Gathering Testing for
Coronavirus Disease 2019)
(Amendment No. 10) Regulations 2021

In exercise of the powers conferred by section 73(1) of the Infectious Diseases Act, the Minister for Health makes the following Regulations:

Citation and commencement

1. These Regulations are the Infectious Diseases (Mass Gathering Testing for Coronavirus Disease 2019) (Amendment No. 10) Regulations 2021 and come into operation on 11 October 2021.

Amendment of regulation 2

2. Regulation 2(1) of the Infectious Diseases (Mass Gathering Testing for Coronavirus Disease 2019) Regulations 2021 (G.N. No. S 273/2021) (called in these Regulations the principal Regulations) is amended —

(a)

by inserting, immediately after the definition of “recovered individual”, the following definition:

“ “relevant assessment activity” means ascertaining the results of an approved test on a respiratory specimen from an individual and recording the results, even if uncertain or invalid;”;

(b)

by deleting the words “testing the presence of SARS‑CoV‑2 in that individual” in the definition of “relevant sampling activity” and substituting the words “a relevant testing activity”; and

(c)

by inserting, immediately after the definition of “relevant sampling activity”, the following definition:

“ “relevant testing activity” means subjecting the respiratory specimen from an individual to an approved test for the purpose of testing the presence of SARS‑CoV‑2 in that individual;”.

Amendment of regulation 8

3. Regulation 8 of the principal Regulations is amended —

(a)

by deleting the words “not more than 2 antigen rapid tests and the test result of one of them is uncertain or invalid” in paragraph (2)(b) and substituting the words “further antigen rapid tests and the test results of those tests are uncertain or invalid except the last”;

(b)

by deleting the words “first and second antigen rapid tests are each” in paragraph (3)(a) and substituting the words “antigen rapid tests are”; and

(c)

by deleting sub‑paragraphs (a) and (b) of paragraph (4) and substituting the following sub-paragraphs:

“(a)

the relevant sampling activity taking the respiratory specimen from the individual was —

(i)	not performed in Singapore, or not performed by or under the direction of an approved test provider where the relevant sampling activity is not self‑administered; or
(ii)	in the case of a self‑administered relevant sampling activity performed by the individual on himself or herself, not supervised by an approved test provider; or

(b)

the relevant testing activity or the relevant assessment activity involving the respiratory specimen from the individual was —

(i)	not performed in Singapore, or not performed by or under the direction of an approved test provider where the relevant testing activity or the relevant assessment activity is not self‑administered; or
(ii)	in the case of a self‑administered relevant testing activity or a self‑administered relevant assessment activity performed by the individual involving the respiratory specimen removed from himself or herself, not supervised by an approved test provider.”.

Amendment of regulation 8A

4. Regulation 8A(4) of the principal Regulations is amended by deleting sub‑paragraphs (d) and (e) and substituting the following sub‑paragraph:

“(d)

the period —

(i)

starting the time (not date) the individual undergoes any approved test that is an antigen rapid test (or the first of any such approved tests if there is more than one) where the test result of the antigen rapid test shows the presence of SARS‑CoV‑2 in that individual; and

(ii)

ending —

(A)	on (and including) the 10th day after the date of the approved test (or of the first approved test, as the case may be) mentioned in sub‑paragraph (i);
(B)	the time (not date) the individual’s test result after undergoing a polymerase chain reaction test, is treated as negative for SARS‑CoV‑2 or an atypical finding for SARS‑CoV‑2; or
(C)	the time (not date) the individual’s test result is treated as negative for SARS‑COV‑2 after the individual undergoes an approved test that is an antigen rapid test where the relevant sampling activity for the antigen rapid test is performed at least 72 hours after the time in sub‑paragraph (i),

whichever is earliest.”.

[G.N. Nos. S 310/2021; S 324/2021; S 367/2021; S 396/2021; S 513/2021; S 542/2021; S 590/2021; S 620/2021; S 682/2021]

Made on 9 October 2021.

NG HOW YUE

Permanent Secretary
(Health Development),
Ministry of Health,
Singapore.

[AG/LEGIS/SL/137/2020/13 Vol. 2]

Search within Legislation